Administration of Vitamin D Metabolites Affects RNA Expression of Xenobiotic Metabolising Enzymes and Function of ABC Transporters in Rats by Klumpp, Karoline et al.
Research Article
Administration of Vitamin D Metabolites Affects RNA
Expression of Xenobiotic Metabolising Enzymes and Function of
ABC Transporters in Rats
Karoline Klumpp,1 Frauke Lange,1 Alexandra S. Muscher-Banse,1 Nadine Schnepel,1
Kathrin Hansen,1 Adrian L. Lifschitz,2 Laura Mate,2 and Mirja R. Wilkens 1
1Institute of Physiology and Cell Biology, University of Veterinary Medicine Hannover, Hanover, Germany
2Laboratory of Veterinary Pharmacology, Faculty of Veterinary Sciences, National University of Central Buenos Aires Province,
B7000 Tandil, Argentina
Correspondence should be addressed to Mirja R. Wilkens; mirja.wilkens@tiho-hannover.de
Received 6 June 2019; Accepted 13 September 2019; Published 9 October 2019
Guest Editor: Ciriaco Carru
Copyright © 2019 Karoline Klumpp et al. -is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
From studies on different species and in cell culture systems, it has been suggested that vitamin D metabolites might affect the
metabolism and elimination of xenobiotics. Although most studies performed on rodents and cell cultures report an upregulation
of respective enzymes and transporters, data from the literature are inconsistent. Especially results obtained with sheep differ from
these observations. As vitamin D metabolites are widely used as feed additives or therapeutics in livestock animals, we aimed to
assess whether these differences indicate species-specific responses or occurred due to the very high dosages used in the rodent
studies. -erefore, we applied treatment protocols to rats that had been used previously in sheep or cattle. Forty-eight female rats
were divided into three treatment and corresponding placebo groups: (1) a single intraperitoneal injection of 1,25-(OH)2D3 or
placebo 12 h before sacrifice; (2) daily supplementation with 25-OHD3 by oral gavage or placebo for 10 days; and (3) a single
intramuscular injection of vitamin D3 10 days before sacrifice. In contrast to a previous study using sheep, treatment of rats with
1,25-dihydroxyvitamin D3 did not result in an upregulation of cytochrome P450 3A isoenzymes (CYP3A), but a decrease was
found in hepatic and intestinal expressions. In addition, a downregulation of P-glycoprotein (P-gp) and breast cancer resistance
protein was found in the brain. Taken together, the stimulating effects of vitamin D metabolites on the expression of genes
involved in the metabolism and elimination of xenobiotics reported previously for rodents and sheep could not be reproduced. In
contrast, we even observed a negative impact on the expression of CYP3A enzymes and their most important regulator, the
pregnane X receptor. Most interestingly, we could demonstrate an effect of treatment with 25-hydroxyvitamin D3 and vitamin D3
on the functional activity of ileal P-glycoprotein (P-gp) using the Ussing chamber technique.
1. Introduction
Due to public interest on the potential beneficial effects not
only on calcium homeostasis and bone metabolism but also
on the possible prevention of diabetes, cancer, inflammatory
bowel diseases, etc., vitamin D supplementation has become
a common practice in many countries in recent years [1, 2].
However, as many products are sold over the counter, the
dosages are often not critically determined by medical
professionals. In livestock including high yielding dairy
cows, high doses of vitamin D are used as a feed additive and
for treatment of imbalances of mineral homeostasis [3–5].
Many xenobiotica are substrates of cytochrome P450
(CYP) 3A4, an enzyme that is involved in the phase I
metabolism of approximately 50% of all therapeutics used in
humans [6]. Absorption and excretion rates of a broad range
of endogenous and exogenous hydrophobic molecules are
substantially determined by the efflux transporter P-glyco-
protein (P-gp). As several compounds can inhibit or induce
its activity, P-gp plays a crucial role in numerous drug-drug
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interactions [7]. It was shown that vitamin Dmetabolites can
be substrates of both CYP3A4 and P-gp [8, 9].
Interestingly, oral supplementation with vitamin D and
UV exposure affecting endogenous synthesis of vitamin D
has been reported to be associated with changes in plasma
concentrations of certain therapeutics. In humans, dosage-
dependent plasma concentrations of tacrolimus and siroli-
mus were found to be decreased in summer [10]. Both
immunosuppressants are substrates of CYP 3A4 [6] and
eliminated by P-gp [11]. In addition, it could be demon-
strated that patients medicated with atorvastatin, a drug that
is also metabolized by CYP3A4, showed lower plasma
concentrations when the treatment was combined with oral
vitamin D supplementation [12]. In contrast, such an in-
teraction could not be detected in a study on intestinal
absorption of the P-gp substrate digoxin [13], and the results
of studies investigating these potential drug-drug in-
teractions in cell culture systems and rodents are in-
consistent too.
Human intestinal cells (Caco-2 and LS180) only express
the CYP3A4 isoenzyme if 1,25-dihydroxyvitamin D3 (1,25-
(OH)2D3) is added to the medium, probably mediated via
the vitamin D receptor (VDR). Likewise, primary human
hepatocytes respond in the same way to such a treatment
although this is not found in all hepatic cell lines. It has been
suggested that VDR might bind to xenobiotic-responsive
elements in certain CYP promoters [14–16]. An upregula-
tion of P-gp induced by hydroxylated vitamin D metabolites
as well as an increased functional activity could also be found
in Caco-2 cells [17].
In rats, the isoforms CYP3A1/23, CYP3A2, CYP3A9,
CYP3A18, and CYP3A62 are expressed with CYP3A9 and
CYP3A62 being themost important isoforms in the intestine
[18–20]. Administration of 1,25-(OH)2D3 and the vitamin D
analog 19nor-1,25-(OH)2D3 resulted in a transient increase
in intestinal RNA expression of CYP3A9 [21]. In contrast,
repeated administration had no effect on CYP3A9 intestinal
RNA expression, but the expression of CYP3A1/23 and
CYP3A proteins was increased [22, 23] as well as renal RNA
expression of CYP3A9 [24]. In sheep, the administration of
1,25-(OH)2D3 led to a pronounced stimulation of both renal
and intestinal CYP3A24 [25], the ovine gene orthologous to
human CYP3A4 [26]. Expression and activity of intestinal
P-gp were not altered in 1,25-(OH)2D3-treated rats [27],
while in sheep, hepatic and intestinal expressions were even
slightly decreased after oral supplementation with 25-
hydroxyvitamin D (25-OHD3) [25]. Results on hepatic P-gp
expression in rats were inconsistent with different dosages
[22], whereas in the kidney and brain of mice, expression
and activity of P-gp were stimulated [28].
To investigate whether the observed discrepancies are
species differences or are the result of the very high dosages
used repeatedly in rodents, we applied treatment protocols
to rats that had been used before in sheep or cattle: 0.5 μg
1,25-(OH)2D3 per kg body weight (BW) intravenously
12 hours before sacrifice, 6 μg 25-hydroxyvitamin D3 (25-
OHD3) per kg BW per os daily for 10 days, and 300 μg
vitamin D3 per kg BW intramuscularly once 10 days before
sacrifice. After sampling, we investigated RNA expression of
genes involved in calcium absorption and vitamin D
metabolism: VDR, pregnane X receptor (PXR), different
CYP3A enzymes, P-gp, and breast cancer resistance protein
(BCRP) as well as the functional activity of ileal P-gp.
2. Materials and Methods
2.1.Animals, Treatments, andSampling. -e protocols of the
animal treatment were approved by the Lower Saxony State
Office for Consumer Protection and Food Safety (33.12-
42502-04-15/1995) and their conduct supervised by the
Animal Welfare Commissioner of the University of Vet-
erinary Medicine Hannover in accordance with the German
Animal Welfare Law.
In the current study, 48 female Sprague Dawley rats aged 8
to 11 weeks (body weight 10 days before sacrifice: 220± 7.0 g)
were kept on a standard chow (ssniff Spezialdia¨ten GmbH,
Soest, Germany) fed ad libitum and maintained under a 12 :
12-hour light and dark cycle. -e animals were divided into
three treatment and corresponding placebo groups: (1) a
single intraperitoneal injection of 1,25-(OH)2D3 (N= 9,
0.5 μg/kg body weight, Decostriol®, mibe GmbH Arznei-mittel, Brehna, Germany) or placebo (N= 7) 12 h before
sacrifice; (2) daily supplementation with 25-OHD3 by oral
gavage (N= 8, 6 μg/kg body weight, Dedrogyl®, DesmaGmbH, Mainz-Kastel, Germany, diluted with tap water to a
total volume of 1ml) or placebo (N=8, 1ml of tap water with
addition of propylene glycole, the nonpharmacological
compound of Dedrogyl®) for 10 days; and (3) a single in-tramuscular injection of vitamin D3 (N = 8, 300 μg/kg body
weight, D3-Vicotrat®, Heyl Chemisch-pharmazeutischeFabrik GmbH & Co. KG, Berlin, Germany) or placebo
(N = 8) 10 days before sacrifice.
-e animals were anesthetized by exposure to carbon
dioxide and sacrificed immediately by exsanguination via
cardiac puncture. Serum samples were prepared and stored
at − 20°C. Tissues for the isolation of RNA were collected
within 10min postmortem and rinsed with ice-cold saline
(0.9%). -e small intestinal epithelia (proximal jejunum and
distal jejunum/ileum, the latter one refers to the segment
directly proximal from that used for the Ussing chamber
experiments) was scraped from the underlying submucosal
and muscle layers with a glass slide. -e tissues were frozen
in liquid nitrogen and stored at − 80°C until analysis. For the
Ussing chamber experiments, the ileum was opened along
the mesenteric line, rinsed with ice-cold 0.9% (w/v) saline,
and kept in ice-cold buffer solution (113.6mM NaCl,
5.4mM KCl, 1.2mM CaCl2, 1.2mM MgCl2, 0.2mM HCl,
0.6mM NaH2PO4, 2.4mM Na2HPO4, 21.0mM NaHCO3,
10mM glucose, and 19.8mM mannitol) aerated with
carbogen. Serosal and muscle layers were peeled off carefully
using forceps, and the epithelia were mounted in the
chambers within 30min after sacrifice.
2.2. Plasma Analyses. Serum was analyzed for total calcium
colorimetrically by the o-cresolphthalein complexone
method [29]. Intra- and interassay coefficients in our lab-
oratory are 5.09% and 6.88%. A commercial ELISA
2 Journal of Chemistry
(25(OH)-Vitamin D direct day ELISA®, ImmundiagnostikAG, Bensheim, Germany) was used to determine serum 25-
OHD concentrations. Intra- and interassay coefficients in
our laboratory and sensitivities are 10.1%, 13.4%, and
6.08 ng/ml. According to the manufacturer, cross-reactivity
with other vitamin D metabolites compared to 25-OHD3 is
67.8% for 25-OHD2 and 100% for 24,25-(OH)2D3.
Measurement of serum concentrations of 1,25-(OH)2D
was carried out by a commercial diagnostic laboratory using
a competitive ELISA following solvent extraction (1,25-
(OH)2-Vitamin D ELISA®, Immundiagnostik AG, Ben-sheim, Germany). Intra- and interassay coefficients and
sensitivities documented and provided by the laboratory are
6.69%, 9.00%, and 4.80 pg/ml. Cross-reactivity with 1,25-
(OH)2D2 compared to 1,25-(OH)2D3 is declared to be 41%.
2.3. Quantification of RNA Expression. Total RNA was iso-
lated using the RNeasy plus Mini Kit (Qiagen, Hilden,
Germany) with genomic DNA eliminator spin columns in
accordance with themanufacturer’s protocol. Concentration
and quality of the RNA were determined by UV absorbance,
and 200 ng was reverse transcribed using random hexamer
primers and TaqMan-reverse-transcription reagents (Ap-
plied Biosystems, Darmstadt, Germany).
RNA expression of β-actin, TRPV6 (transient receptor
potential vanilloid type 6), CaBP-D9K (calbindin-D9K),
PMCA1b (plasma membrane calcium ATPase 1b),
CYP27B1 (cytochrome P450 27B1, 1α-hydroxylase),
CYP24A1 (24-hydroxylase), VDR (vitamin D receptor) and
PXR (pregnane X receptor), CYP3A9, CYP3A18, CYP3A62,
MDR1a, and MDR1b (ABCB1, P-gp, P-glycoprotein), and
BCRP (ABCG2, breast cancer resistance protein) was de-
termined using SYBR Green® PCR assays. Specific primers(Table 1) were purchased from Life Technologies (Darm-
stadt, Germany). Reaction mixtures (20 μl) contained KAPA
SYBR FASTUniversalMasterMix (PEQLAB Biotechnologie
GmbH, Erlangen, Germany), specific primers (200 nM), and
16 ng reverse transcribed RNA. PCR products were am-
plified (95°C, 3min; 40 cycles of 95°C, 10 s; and 60°C, 30 s)
and detected on a real-time PCR cycler (CFX96TM, Bio-
Rad, Munich, Germany). -e thermal profile for melt curve
determination began with an incubation of 10min at 55°C
with a gradual increase in temperature (0.5°C/10 s) to 95°C.
Expression of GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) was determined using gene-specific
TaqMan® primers and probes (TIB Molbiol GmbH, Berlin,Germany). Reaction mixtures (20 μl) contained TaqMan®Universal PCR Master Mix (-ermo Fisher, Darmstadt,
Germany), 50 pM specific primers, 25 pM specific probe, and
16 ng reverse-transcribed RNA. PCR products were am-
plified as follows: 50°C, 2min; 95°C, 10min; 40 cycles of
95°C, 15 s; and 60°C, 1min.
Absolute copy numbers were determined using calibra-
tion curves generated with cloned PCR fragment standards as
described elsewhere [31]. Efficiency of the PCR assays tested
in advance for dilutions of cDNA and cloned standard ranged
from 85 to 105%. Specificity of the amplicons was verified
using NCBI Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Parallel PCR assays for each gene target were performed with
cDNA samples, genomic standards, and a no-template
control with water. Expression of target genes was normalized
using the expression of GAPDH or β-actin as stable expressed
reference genes during treatments. Each series of experiments
was carried out twice.
2.4. Using Chamber Experiments. For each ileum, six pieces
of tissue were mounted between the two halves of incubation
chambers with an exposed area of 0.50 cm2. -ereby, the
Ussing chambers were separated in a serosal and a mucosal
compartment each connected to circulation reservoirs filled
with respective buffer solutions (113.6mM NaCl, 5.4mM
KCl, 1.2mM CaCl2, 1.2mM MgCl2, 0.2mM HCl, 0.6mM
NaH2PO4, 2.4mM Na2HPO4, 21.0mM NaHCO3, 10mM
glucose, and 19.8mM mannitol) which were maintained at
38°C by water jackets and continuously stirred and aerated
with carbogen by a gas lift system. A computer-controlled
voltage clamp device (Mussler Scientific Instruments,
Aachen, Germany) was used to determine tissue conduc-
tance (Gt) and transepithelial potential difference (PDt) with
reference to the mucosal side. All experiments were carried
out under open-circuit current conditions.
Activity of P-gp was determined by the use of rhoda-
mine-123 (Sigma-Aldrich Chemie GmbH, Schnelldorf,
Germany) that was added to a final concentration of 26 μM
either to the serosal (four chambers per animal) or to the
mucosal side of the tissue (two chambers per animal). Two
of the four chambers with the serosal side as donor
compartment were additionally provided with 100 μM
verapamil (Sigma-Aldrich Chemie GmbH, Schnelldorf,
Germany) to inhibit P-gp-mediated transport of rhoda-
mine-123. After an equilibration period of 30min, six
samples of 400 μl each were taken at intervals of 30min and
this volume was immediately replaced by 400 μl of the
respective buffer solution. -e concentration of rhoda-
mine-123 in the acceptor compartment was measured at
485 nm (extinction) and 520 nm (emission), calculated by
interpolation from a standard curve and corrected cu-
mulatively for the previously removed samples (Infinite
M200, Tecan GmbH, Crailsheim, Germany). -e secretory
response of the intestinal segments to forskolin (10 μM,
added to the serosal side, Sigma-Aldrich Chemie GmbH,
Schnelldorf, Germany) represented by the increase in PDt
served as a parameter to survey the viability of the epi-
thelium at the end of the experiments.
2.5. Statistical Analyses and Presentation of Data. As all
approaches included a placebo treatment administered
through the same route, results on RNA expression were
compared by Student’s t test for unpaired observations for
each treatment versus the respective control (P< 0.05∗;
P< 0.01∗∗; P< 0.001∗∗∗). Data are presented in relation to
the corresponding control group. A second-order poly-
nomial model could be calculated for rhodamine-123 net
increase over time. In addition, results were compared by 2-
way ANOVA for repeated measures (time, treatment, and
interaction) followed by Bonferroni’s posttest. All statistical
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analyses including the linear regression analyses were done
using GraphPad Prism Version 6.00 (GraphPad Software,
San Diego, California, USA).
3. Results
3.1. Body Weight and Serum Parameters. All animals were
clinically healthy during the study. Body weight and serum
parameters at sacrifice are presented in Table 2. Body weight
was not affected. Treatment with 1,25-(OH)2D3 resulted in
significantly greater serum concentrations of 1,25-(OH)2D3
(P< 0.001) and total calcium (P< 0.001), while adminis-
tration of 25-OHD3 and vitamin D3 only increased serum
concentrations of 25-OHD3 (P< 0.001; P< 0.001).
3.2. RNA Expression. RNA expression of genes involved in
vitamin D metabolism, transepithelial calcium transport,
metabolism, and elimination of xenobiotics as well as nu-
clear receptors is given in Tables 3–7.
Only intraperitoneal administration of 1,25-(OH)2D3
resulted in a significant downregulation of the renal
CYP27B1 (P< 0.001, Table 5), while the renal CYP24A1
(P< 0.001, Table 5), renal VDR (P< 0.05, Table 5), and the
intestinal calcium transport protein CaBPD9K were signifi-
cantly upregulated (P< 0.001, Table 3). In addition, the
treatment increased the RNA expression of PXR in the brain
by trend (P � 0.053, Table 7) and decreased the RNA ex-
pression of hepatic PXR (P< 0.05, Table 6) and CYP3A18
(P< 0.05, Table 6), renal PXR (P< 0.05, Table 5), and intestinal
CYP3A9 (P< 0.05, Table 4). RNA expression of both efflux
transporters investigated, MDR1a and BCRP, and was sig-
nificantly decreased in the brain (P< 0.01; P< 0.05, Table 7).
While intramuscular treatment with vitamin D3 only
exerted a decreasing effect on renal PXR (P< 0.05, Table 5),
oral supplementation with 25-OHD3 did not affect any of the
genes investigated.
Regression analyses revealed linear correlations between
the expression of PXR and CYP3A18 (y� 2.220± 0.391
x–0.022± 0.011, r2: 0.47, P< 0.001) and MDR1a
(y� 1.290± 0.121 x–0.007± 0.003, r2: 0.75, P< 0.001) in the
proximal jejunum in all groups except for rats treated with
0.5 μg/kg body weight 12 h before sacrifice (Figure 1).
3.3. Ileal P-gpActivity. While no effect was found in animals
treated with 1,25-(OH)2D3 12 hours before sacrifice (data
not shown), rats treated with 25-OHD3 or vitamin D3
showed a more pronounced inhibition of probably P-gp-
mediated secretion of rhodamine-123 after addition of ve-
rapamil to the mucosal compartment of the Ussing chamber
(P< 0.001). Analysis of rhodamine-123 net increase
Table 1: Primers used for quantitative RT-PCR assays.
Gene and source Sequence Product size
GAPDH
NM_017008.4
for 5′-TTGTCAGCAATGCATCCTGC-3′
rev 5′-CGGCATGTCAGATCCACAAC-3′
Probe: 5′-6FAM-TGGCCCCTCTGGAAAGCTGTGGCG-BBQ 307
β-actin
[30]
for 5′-AAGTCCCTCACCCTCCCAAAAG-3′
rev 5′-AAGCAATGCTGTCACCTTCCC-3′ 97
BRCP
XM_006236573.3
for 5′-AGTCCGGAAAACAGCTGAGA-3′
rev 5′-CAAGATGACGTTGTGATGGG-3′ 235
CaBP-D9K
NM_012521.2
for 5′-TGAGCGCTAAGAAATCTCCCG-3′
rev 5′-GCTGGGGAACTCTGACTGAAT-3′ 125
CYP3A9
NM_147206.2
for 5′-CCTGGCTGCTCCTGGTTATC-3′
rev 5′-AAAGGTTTGGGCCCAGGAAT-3′ 100
CYP3A18
NM_145782.1
for 5′-CTACGGTGATGGCATGTGGA-3′
rev 5′-CATTGGCCCAAAACACCGAC-3′ 178
CYP3A62
NM_001024232.1
for 5′-TCTTGCATACCGCCATGGAT-3′
rev 5′-AAAGCTCCGACGGTTTGTGA-3′ 175
CYP24A1
NM_201635.2
for 5′-CTCGGACCCTTGACAAACCA-3′
rev 5′-CCGAATGGGAGATGAGCGAA-3′ 184
CYP27B1
NM_053763.1
for 5′-TACCCCTGCTAAAGGCTGTGA-3′
rev 5′-GAGTTGGGTTCCCGAAACTGG-3′ 181
MDR1a
NM_133401.1
for 5′-TCTGGCGGCCATTATCCAT-3′
rev 5′-TCATACTACGGTTGTTTCCTACATTTG-3′ 101
MDR1b
NM_012623.2
for 5′-TGAATCCCAAAGTGACACTGGT-3′
rev 5′-ATACTTCTGCGAATTGATCTCCTTATT-3′ 87
PMCA1b
NM_053311.1
for 5′-AATGCTTTCCAGAGTGGAGGT-3′
rev 5′-TCGGATACCCCACAGGAGT-3′ 148
PXR
NM_052980.2
for 5′-GCGTCATCAACTTCGCCAAA-3′
rev 5′-TTCTGGAAGCCGCCATTAGG-3′ 193
TRPV6
NM_053686.1
for 5′-GAGCACAGGTTGTGGCTACT-3′
rev 5′-TCCACCCTCAAGAACCAGCG-3′ 122
VDR
[24]
for 5′-ACAGTCTGAGGCCCAAGCTA-3′
rev 5′-TCCCTGAAGTCAGCGTAGGT-3′ 103
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Table 2: Body weight and serum parameters of rats treated with different vitamin D metabolites.
1,25-(OH)2D3
(0.5 μg/kg body weight, administered
intraperitoneally once, 12 h before
sacrifice)
25-OHD3
(6 μg/kg body weight, administered
daily by oral gavage for 10 days)
Vitamin D3
(300 μg/kg body weight, administered
intramuscularly, once 10 days before
sacrifice)
Body weight (g) 254± 7.74(241± 6.17) 263± 4.62(258± 10.2) 246± 6.10(247± 7.30)
25-OHD3
(ng/ml)
32.0± 4.02
(23.1± 3.88) 87.9± 12.0∗∗∗(25.6± 1.80) 154.2± 14.2∗∗∗(31.5± 4.73)
1,25-(OH)2D3
(pg/ml)
237.6± 21.2∗∗∗
(37.4± 7.61) 27.0± 3.32(39.3± 7.37) 27.1± 1.78(30.9± 3.51)
Total calcium
(mM)
2.85± 0.03∗∗∗
(2.68± 0.03) 2.71± 0.02(2.70± 0.03) 2.64± 0.03(2.69± 0.03)
Mean± SEM of respective control groups are given in brackets; asterisks indicate significant differences between treatment and control groups; ∗∗∗P< 0.001,∗∗P< 0.01.
Table 3: RNA expression in the proximal jejunum of rats treated with different vitamin D metabolites normalized to GAPDH.
1,25-(OH)2D3
(0.5 μg/kg body weight, administered
intraperitoneally once, 12 h before
sacrifice)
25-OHD3
(6 μg/kg body weight, administered daily
by oral gavage for 10 days)
Vitamin D3
(300 μg/kg body weight, administered
intramuscularly, once 10 days before
sacrifice)
TRPV6 0.879± 0.142(1± 0.08) 1.187± 0.267(1± 0.148) 1.741± 0.938(1± 0.161)
CaBP-D9K
4.773± 0.418∗∗∗
(1± 0.231) 0.469± 0.185(1± 0.342) 0.437± 0.076(1± 0.480)
PMCA1b 0.790± 0.082(1± 0.0731)´ 1.054± 0.156(1± 0.061) 1.019± 0.286(1± 0.283)
VDR 1.118± 0.107(1± 0.254) 1.489± 0.362(1± 0.148) 2.630± 1.682(1± 0.113)
PXR 1.350± 0.165(1± 0.150) 1.430± 0.271(1± 0.122) 0.958± 0.087(1± 0.080)
CYP3A9 0.756± 0.130(1± 0.148) 1.219± 0.125(1± 0.207) 1.056± 0.219(1± 0.162)
CYP3A18 0.936± 0.108(1± 0.169) 1.339± 0.162(1± 0.091) 1.226± 0.203(1± 0.095)
CYP3A62 0.907± 0.130(1± 0.123) 1.163± 0.139(1± 0.120) 1.049± 0.198(1± 0.144)
MDR1a 1.154± 0.150(1± 0.252) 1.723± 0.393(1± 0.151) 1.174± 0.168(1± 0.193)
Means± SEM of respective control groups set to 1 are given in brackets; asterisks indicate significant differences between treatment and control groups;∗∗∗P< 0.001.
Table 4: RNA expression in the distal jejunum/ileum of rats treated with different vitamin D metabolites normalized to GAPDH.
1,25-(OH)2D3
(0.5 μg/kg body weight, administered
intraperitoneally once, 12 h before
sacrifice)
25-OHD3
(6 μg/kg body weight, administered daily
by oral gavage for 10 days)
Vitamin D3
(300 μg/kg body weight, administered
intramuscularly, once 10 days before
sacrifice)
VDR 0.976± 0.061(1± 0.073) 0.732± 0.060(1± 0.350) 1.027± 0.068(1± 0.089)
PXR 0.991± 0.083(1± 0.128) 1.163± 0.083(1± 0.131) 1.178± 0.105(1± 0.086)
CYP3A9 0.607± 0.088∗∗(1± 0.055) 1.546± 0.222(1± 0.185) 1.096± 0.162(1± 0.170)
CYP3A18 0.763± 0.126(1± 0.082) 1.061± 0.113(1± 0.160) 1.381± 0.239(1± 0.170)
CYP3A62 0.775± 0.082(1± 0.064) 1.302± 0.105(1± 0.146) 0.838± 0.074(1± 0.138)
MDR1a 1.089± 0.071(1± 0.074) 1.299± 0.191(1± 0.159) 1.058± 0.160(1± 0.242)
Mean± SEM of respective control groups set to 1 are given in brackets; asterisks indicate significant differences between treatment and control groups;∗∗P< 0.01.
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Table 6: RNA expression in the liver of rats treated with different vitamin D metabolites normalized to β-actin.
1,25-(OH)2D3
(0.5 μg/kg body weight, administered
intraperitoneally once, 12 h before
sacrifice)
25-OHD3
(6 μg/kg body weight, administered daily
by oral gavage for 10 days)
Vitamin D3
(300 μg/kg body weight, administered
intramuscularly, once 10 days before
sacrifice)
VDR 1.398± 0.198(1± 0.092) 1.014± 0.204(1± 0.184) 1.000± 0.190(1± 0.198)
PXR 0.666± 0.096∗(1± 0.120) 0.889± 0.137(1± 0.211) 0.950± 0.094(1± 0.161)
CYP3A9 1.157± 0.235(1± 0.196) 0.983± 0.064(1± 0.122) 1.223± 0.119(1± 0.104)
CYP3A18 0.661± 0.094∗(1± 0.097) 0.789± 0.071(1± 0.118) 1.115± 0.175(1± 0.074)
CYP3A62 1.087± 0.183(1± 0.084) 0.875± 0.089(1± 0.135) 1.166± 0.119(1± 0.062)
MDR1a 0.828± 0.099(1± 0.139) 0.946± 0.107(1± 0.102) 1.218± 0.149(1± 0.158)
MDR1b 1.398± 0.254(1± 0.222) 0.813± 0.097(1± 0.230) 1.437± 0.256(1± 0.152)
Means± SEM of respective control groups set to 1 are given in brackets; asterisks indicate significant differences between treatment and control groups;∗P< 0.05.
Table 7: RNA expression in the brain of rats treated with different vitamin D metabolites normalized to GAPDH.
1,25-(OH)2D3
(0.5 μg/kg body weight, administered
intraperitoneally once, 12 h before
sacrifice)
25-OHD3
(6 μg/kg body weight, administered daily
by oral gavage for 10 days)
Vitamin D3
(300 μg/kg body weight, administered
intramuscularly, once 10 days before
sacrifice)
VDR 0.853± 0.051(1± 0.193) 0.983± 0.054(1± 0.111) 0.950± 0.073(1± 0.106)
PXR 2.128± 0.992#(1± 0.216) 1.045± 0.045(1± 0.115) 1.710± 0.656(1± 0.168)
BCRP 0.703± 0.072∗(1± 0.071) 1.145± 0.107(1± 0.125) 1.371± 0.183(1± 0.095)
MDR1a 0.719± 0.052∗∗(1± 0.065) 0.971± 0.066(1± 0.070) 1.045± 0.084(1± 0.068)
MDR1b 0.975± 0.109(1± 0.209) 1.027± 0.162(1± 0.171) 1.187± 0.170(1± 0.137)
Means± SEM of respective control groups set to 1 are given in brackets; asterisks indicate significant differences between treatment and control groups;
#P� 0.053, ∗P< 0.05, and ∗∗P < 0.01.
Table 5: RNA expression in the kidney of rats treated with different vitamin D metabolites normalized to GAPDH.
1,25-(OH)2D3
(0.5 μg/kg body weight, administered
intraperitoneally once, 12 h before
sacrifice)
25-OHD3
(6 μg/kg body weight, administered daily
by oral gavage for 10 days)
Vitamin D3
(300 μg/kg body weight, administered
intramuscularly, once 10 days before
sacrifice)
VDR 1.488± 0.135∗(1± 0.066) 0.833± 0.076(1± 0.072) 0.775± 0.075(1± 0.089)
PXR 0.804± 0.063∗(1± 0.048) 0.905± 0.082(1± 0.075) 0.729± 0.092∗(1± 0.068)
CYP24A1 32.28± 5.041∗∗∗(1± 0.276) 1.292± 0.464(1± 0.464) 1.958± 0.530(1± 0.202)
CYP27B1 0.187± 0.026∗∗∗(1± 0.152) 1.034± 0.264(1± 0.368) 0.429± 0.104(1± 0.558)
MDR1a 1.240± 0.078(1± 0.082) 1.295± 0.142(1± 0.147) 0.653± 0.065(1± 0.345)
MDR1b 0.915± 0.147(1± 0.253) 1.227± 0.366(1± 0.205) 1.193± 0.291(1± 0.157)
Means± SEM of respective control groups set to 1 are given in brackets; asterisks indicate significant differences between treatment and control groups;∗∗∗P< 0.001, ∗P< 0.05.
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over time revealed a second-order polynomial model
(y� b0 + b1 · x+ b2 · x2, Figure 2) that differed between pla-
cebo and treatment groups for the animals that had received
25-OHD3 (b0: 1.36± 6.96 and 1.04± 8.85, b1: − 0.118± 0.218
and − 0.019± 0.278, b2: 0.0031± 0.0014 and 0.0041± 0.0018,
P< 0.001) as well as for those treated with vitamin D3 (b0:
0.78± 4.89 and 0.93± 6.05, b1: − 0.056± 0.153 and
0.053± 0.190, b2: 0.0028± 0.0010 and 0.0036± 0.0012,
P< 0.001).When compared with 2-way ANOVA for repeated
measures followed by Bonferroni’s posttest, significant effects
could be confirmed for the factors time (P< 0.001) and in-
teraction of time and treatment (P< 0.05) for the 25-OHD3-
group with significant differences between the concentrations
determined after 150min of incubation (P< 0.05). For ani-
mals treated with vitamin D3, significant effects could be
confirmed for the factors time (P< 0.001), treatment
(P< 0.05), and interaction of time and treatment (P< 0.01)
with significant differences between the concentrations de-
termined after 120min (P< 0.05) and 150min of incubation
(P< 0.01).
4. Discussion
Vitamin D responsive elements have been shown in the
promotor regions of human MDR1 and CYP3A4 genes as
well as in that of the rat CYP3A9 gene [21, 32, 33]. In
contrast to some results previously obtained in rats and
sheep treated with 1,25-(OH)2D3 [25, 28], neither iso-
enzymes belonging to the CYP3A family investigated nor
MDR1a/b was upregulated by intraperitoneal administra-
tion of 1,25-(OH)2D3 in the present study. It should be noted
that, in most previous studies with rodents, 1,25-(OH)2D3
was administered repeatedly or at higher doses. Our serum
analysis data and that of RNA expression of genes involved
in vitamin D metabolism and calcium transport indicate
clearly that the vitamin D metabolites were administered
correctly and absorbed efficiently. However, from the results
on CYP24A1 and CYP27B1 expression, it might be con-
cluded that rats are generally less sensitive to 25-OHD3 than
sheep [25].
In addition, the different response in comparison to
sheep could be explained by species-dependent induction of
CYP3A enzymes. -e predominant regulator of CYP3A
enzymes is PXR [34]. -e human PXR has been shown to
bind hydroxylated vitamin Dmetabolites [35]. In contrast to
other members of the nuclear receptor family, a comparison
of the PXR sequences from different mammalian species
showed that the proteins share less than 80% amino acid
identity in their ligand binding domain (LBD) [36]. -e
striking differences in the LBD are assumed to be responsible
for the selectivity in ligand binding and thus for the dif-
ferences observed in respect to the induction profiles. For
example, rifampicin, but not dexamethasone, induces
CYP3A expression in human liver cells, while rat liver cells
respond to dexamethasone but not to rifampicin [37]. As
differences in the activity of enzymatic biotransformation
could be found even between sheep and goats [38] or when
different cattle breeds were compared [39], results on
pharmacokinetics cannot be easily extrapolated from one
species or breed to another.
-e observation that none of the intestinal CYP3A en-
zymes investigated was upregulated with the 1,25-(OH)2D3-
treatment is in line with results from Xu et al., who found
a selective induction of CYP3A1/23, the isoform that was
not addressed here [23]. However, interestingly, hepatic
CYP3A18 as well as intestinal CYP3A9 RNA expression were
both downregulated in the present study.-is contrasts with a
report of Khan et al. [40], where no effect of 1,25-(OH)2D3 on
rat intestinal and hepatic CYP3A9 could be found, although
the same treatment induced an upregulation of CYP3A4 in
human tissues. In the present study, a reduction in PXR
expression could be shown in the liver and the kidney with
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Figure 1: Regression analyses revealing linear correlations between the expression of PXR and CYP3A18 (y� 2.220± 0.391 x–0.022± 0.011,
r2: 0.47, P< 0.001) and MDR1a (y� 1.290± 0.121 x–0.007± 0.003, r2: 0.75, P< 0.001) in the proximal jejunum in all groups except for rats
treated with 0.5 μg/kg body weight 12 h before sacrifice.
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1,25-(OH)2D3-treatment and also in the kidney with vitamin
D3-treatment, but the same 1,25-(OH)2D3-protocol stimulated
renal PXR expression in sheep [25]. Although other important
nuclear receptors like the constitutive androstane receptor and
the liver X receptor were not included in this study, these results
further underline the relevance of species-specific mechanisms
of CYP3A induction. At least for the liver, the response of
CYP3A18 expression observed in our rats might bemediated by
the decreased expression of PXR that could affect the activation
by endogenous ligands [40]. PXR expression has been shown to
correlate with CYP3A expression in humans [41]. In the present
study, such a correlation with PXR could only be found for the
expression of CYP3A18 and MDR1a in the proximal jejunum.
Interestingly, no linear relationship could be revealed for rats
treated with 1,25-(OH)2D3 (Figure 1). -is observation might
indicate an interference of the treatment with regulatory
pathways involving PXR.
-e effect of the treatment with 25-OHD3 and vitamin
D3 on intestinal activity of P-gp only became apparent after
inhibition of P-gp with verapamil. In both treated groups,
the inhibition seemed to last longer than in the respective
control groups (Figure 2). -e use of rhodamine-123 as a
P-gp-substrate and verapamil as a P-gp-inhibitor is well
established [42–44]. However, a significant efflux of rho-
damine-123 mediated by other transport proteins, such as
multidrug-related-proteins (MRPs), has to be considered
[45, 46]. In the present study, the contribution of other
transporters to the net increase of rhodamine-123 in the
mucosal compartment has not been investigated. Besides a
variation in the abundance of efflux transporters in the
animals treated with vitamin D metabolites, alterations in
the expression pattern or activity of CYP3A enzymes might
explain the different responses to the inhibition of P-gp.
Verapamil itself is metabolized by intestinal CYP3A en-
zymes [47]. Although we could not find any alterations in
the RNA expression of the CYP3A isoenzymes investigated,
it might be speculated that administration of 25-OHD3 and
vitamin D3 led to a change in the relative activity of the
different isoforms of CYP3A enzymes resulting in a slower
metabolism of the applied inhibitor.
On the other hand, the observed effect might be a direct
effect of vitamin D metabolites on P-gp function. Inhibition
of P-gp cannot only occur by influencing its expression but
also by alteration of the ATPase activity or competition for
binding sites. Although verapamil competes with other
substrates for the P-gp binding sites, it also increases its
ATPase activity [48]. Progesterone and desoxycorticoster-
one diminish this stimulating effect of verapamil in a dose-
dependent manner [49]. Recently, it could be demonstrated
that 25-OHD3 and vitamin D3 decrease the verapamil-in-
duced ATPase activity of P-gp in membranes of Sf9 insect
cells overexpressing human P-gp too, while under basal
conditions, only vitamin D3 exerted a slight effect [8]. -is is
in line with our observation that significant effects could be
found for rhodamine-123 transport only after addition of
verapamil.
In brain tissues, we investigated P-gp and BCRP because
these transporters share a broad range of substrates and
BCRP is upregulated in the blood-brain barrier of MDR1a
k.o. mice [50, 51]. In contrast to Durk et al. [52], we did not
find an upregulation but rather a significant downregulation
of MDR1a and BCRP with the 1,25-(OH)2D3 treatment.
Given that our treatment induced expression and activity of
CYP24A1, it can be assumed that as a side-effect there was an
increase in vitamin Dmetabolites hydroxylated at carbon 24.
In fish and chickens, 24,25-(OH)2D3 has been demonstrated
to exert opposite effects to 1,25-(OH)2D3, e.g., a decrease in
calcium absorption [53, 54]. Whether such negative impacts
of vitamin metabolites hydroxylated at carbon 24 could also
play a role in the regulation of nonclassical vitamin D re-
sponsive genes has not yet been investigated. But if there
were such an effect, it could probably be overcome by the
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Figure 2: Net increase in the mucosal concentration of rhodamine-123 (minus increase in serosal concentration) after inhibition of
rhodamine-123 transport by addition of verapamil to the mucosal compartment. Given are results obtained with ileal preparations of rats
treated with 6 μg 25-hydroxyvitamin D3 (25-OHD3) per kg BW per os daily for 10 days or 300 μg vitamin D3 per kg BW intramuscularly
once 10 days before sacrifice.
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much higher and/or repeatedly administered dosage of 1,25-
(OH)2D3 in these reported studies. Another explanation
could be an interaction between VDR, PXR, and the estrogen
receptor or respective estrogen responsive elements in
certain promoters. BCRP is downregulated in brain tissues
by 17β-estradiol [55]. At least in breast cancer cells, 1,25-
(OH)2D3 interacts with estrogen-responsive elements [56].
In addition, metabolic pathways induced by the upregula-
tion of PXR could affect the tissue concentration of estrogens
[57, 58].
In summary, our results show that the stimulating effects
of vitamin Dmetabolites on the expression of genes involved
in the metabolism and elimination of xenobiotics previously
reported for rats and cell culture systems and, in case of
CYP3A also in sheep, could not be reproduced using the
treatment protocol applied here. However, alterations of
P-gp activity as well as an impact on the expression of some
CYP3A isoenzymes and the transcription factor PXR cannot
be excluded.
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